NovoCure Files 8-K: Regulation FD Disclosure Issued
Ticker: NVCR · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0001645113
| Field | Detail |
|---|---|
| Company | Novocure Ltd (NVCR) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2026 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulation-fd, disclosure, corporate-action
TL;DR
**NovoCure just dropped an 8-K with a Regulation FD disclosure, check EX-99.1 for the scoop!**
AI Summary
NovoCure Ltd filed an 8-K on March 26, 2026, under Item 7.01, Regulation FD Disclosure, indicating a significant announcement or event that the company wants to make public. This filing includes an exhibit, EX-99.1, which likely contains the details of this disclosure. For investors, this matters because Regulation FD disclosures often contain material non-public information that could impact the stock price, making it crucial to review the exhibit for specific details about NovoCure's operations or future outlook.
Why It Matters
This filing signals that NovoCure has released important information that could affect its stock value, requiring investors to examine the attached exhibit for details.
Risk Assessment
Risk Level: medium — The risk is medium because the specific content of the Regulation FD disclosure is not detailed in the 8-K summary, meaning its impact on the stock is currently unknown.
Analyst Insight
A smart investor would immediately access and review Exhibit 99.1 to understand the specific details of the Regulation FD disclosure and assess its potential impact on NovoCure Ltd's future performance and stock price.
Key Numbers
- 26690 — Size of 8-K HTML document (Indicates the size of the primary filing document.)
- 14859 — Size of Exhibit 99.1 (Indicates the size of the key disclosure document.)
Key Players & Entities
- NovoCure Ltd (company) — the filer of the 8-K
- 0001645113 (company) — NovoCure Ltd's CIK number
- 2026-03-26 (date) — the filing and acceptance date of the 8-K
Forward-Looking Statements
- NovoCure Ltd's stock price will react to the information contained in Exhibit 99.1. (NovoCure Ltd) — high confidence, target: 2026-03-27
FAQ
What is the purpose of NovoCure Ltd's 8-K filing on March 26, 2026?
NovoCure Ltd filed an 8-K on March 26, 2026, primarily under Item 7.01, Regulation FD Disclosure, indicating a public release of material non-public information.
What specific item number is highlighted in this 8-K filing?
The specific item number highlighted in this 8-K filing is Item 7.01, which pertains to Regulation FD Disclosure.
What exhibit is included with this 8-K filing that likely contains the details of the disclosure?
Exhibit EX-99.1, titled 'p4datapr.htm', is included with this 8-K filing and likely contains the detailed information of the Regulation FD disclosure.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on March 26, 2026, at 07:00:57.
What is NovoCure Ltd's CIK number as stated in the filing?
NovoCure Ltd's CIK number, as stated in the filing, is 0001645113.
Filing Stats: 620 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2026-03-26 07:00:57
Filing Documents
- nvcr-20260326.htm (8-K) — 26KB
- p4datapr.htm (EX-99.1) — 15KB
- 0001645113-26-000023.txt ( ) — 159KB
- nvcr-20260326.xsd (EX-101.SCH) — 2KB
- nvcr-20260326_lab.xml (EX-101.LAB) — 21KB
- nvcr-20260326_pre.xml (EX-101.PRE) — 12KB
- nvcr-20260326_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 26, 2026, the Company issued a press release announcing positive results from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq)*, gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement in disease control rate (DCR) compared to the DCR reported in the Phase 3 MPACT study used as the historical control 1 . The DCR in patients treated with TTFields therapy concomitantly with atezolizumab and gem/nab-pac (N=78) was 74.4% compared to a DCR of 48% in patients receiving gem/nab-pac alone (N=431) in the historical control (difference = 26.4%, 1-sided p-value < 0.001). *Tecentriq (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. 1 Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased Survival in Pancreatic Cancer with nabPaclitaxel plus Gemcitabine. The New England Journal of Medicine. 2013;369(18):1691–170. The information contained in this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated March 26, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: March 26, 2026 By: /s/ Christoph Brackmann Name: Christoph Brackmann Title: Chief Financial Officer